Skip to content
2000
image of Clinicopathological and Molecular Comparative Analysis of Hereditary vs. Sporadic Fumarate Hydratase-deficient Leiomyomatosis and Renal Carcinoma

Abstract

Introduction

FLRCC is a rare renal carcinoma subtype caused by FH mutations, categorized into hereditary (germline mutations) and sporadic (somatic mutations) forms. These forms are clinically and pathologically similar, complicating differentiation without genetic testing. The aim of this study is to investigate the clinicopathological and molecular genetic differences between hereditary and sporadic fumarate hydratase (FH)-deficient leiomyomatosis and renal cell carcinoma (FLRCC) to improve diagnostic accuracy and clinical management.

Method

A retrospective analysis of 14 FLRCC patients was conducted(May 2020-August 2023). Immunohistochemistry (FH, 2SC, p16), HE staining, and next-generation sequencing (NGS) of tumor tissues and blood leukocytes were performed.

Results

The 14 patients with FH-deficient leiomyoma were 25-54 years old, with a mean age of 36.21 ± 8.16. 78.5% (11/14) had clinical symptoms and multiple, large-sized fibroids (median maximum volume was 75 mm). Patients with leiomyoma and FH deficiency were divided into hereditary and sporadic FLRCC based on FH gene sequencing. Patients with HLRCC had an earlier onset, and the serum tumor marker CA125 was more significant. Moreover, tumor tissues from patients with hereditary and sporadic FH-deficient LRCC differed in immunohistochemical and HE staining characteristics, including more positive p16 and greater susceptibility to invasion and metastasis in patients with HLRCC, as well as malignant proliferation in patients with sporadic FH-deficient LRCC.

Discussion

Although limited by sample size, our preliminary findings indicated subtle differences in the age of onset, as well as immunohistochemical and histopathological features of hereditary and sporadic FH-deficient LRCC, facilitating the understanding and clinical diagnosis of FLRCC.

Conclusion

In clinical diagnosis, all information should be fully integrated, and a comprehensive judgment should be made to make a correct pathological diagnosis and provide targeted treatment for patients with an FH gene mutation.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010400394250901101048
2025-10-17
2025-10-30

  • From This Site

    /content/journals/cpb/10.2174/0113892010400394250901101048
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Toro J.R. Nickerson M.L. Wei M.H. Warren M.B. Glenn G.M. Turner M.L. Stewart L. Duray P. Tourre O. Sharma N. Choyke P. Stratton P. Merino M. Walther M.M. Linehan W.M. Schmidt L.S. Zbar B. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 2003 73 1 95 106 10.1086/376435 12772087
    [Google Scholar]
  2. Dobyns A.C. Coutelle N.A. Suthumphong C.Y. Rodriguez P.E. Castro G. Varella M.H. Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007–2015. Eur. J. Cancer Prev. 2022 31 2 172 177 10.1097/CEJ.0000000000000689 34115692
    [Google Scholar]
  3. Moch H. Cubilla A.L. Humphrey P.A. Reuter V.E. Ulbright T.M. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur. Urol. 2016 70 1 93 105 10.1016/j.eururo.2016.02.029 26935559
    [Google Scholar]
  4. Moch H. Amin M.B. Berney D.M. Compérat E.M. Gill A.J. Hartmann A. Menon S. Raspollini M.R. Rubin M.A. Srigley J.R. Hoon Tan P. Tickoo S.K. Tsuzuki T. Turajlic S. Cree I. Netto G.J. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours. Eur. Urol. 2022 82 5 458 468 10.1016/j.eururo.2022.06.016 35853783
    [Google Scholar]
  5. Schmidt L. Linehan W.M. Hereditary leiomyomatosis and renal cell carcinoma. Int. J. Nephrol. Renovasc. Dis. 2014 7 253 260 10.2147/IJNRD.S42097 25018647
    [Google Scholar]
  6. Kennedy J.M. Wang X. Plouffe K.R. Dhanasekaran S.M. Hafez K. Palapattu G.S. Else T. Weizer A.Z. Morgan T.M. Spratt D.E. Davenport M.S. Chinnaiyan A.M. Udager A.M. Mehra R. Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. Med. Oncol. 2019 36 9 74 10.1007/s12032‑019‑1297‑6 31332543
    [Google Scholar]
  7. Lau H.D. Chan E. Fan A.C. Kunder C.A. Williamson S.R. Zhou M. Idrees M.T. Maclean F.M. Gill A.J. Kao C.S. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am. J. Surg. Pathol. 2020 44 1 98 110 10.1097/PAS.0000000000001372 31524643
    [Google Scholar]
  8. Lin J. Kamamia C. Shriver C.D. Zhu K. Race and renal cell carcinoma stage at diagnosis: An analysis of the Surveillance, Epidemiology, and End Results data. Eur. J. Cancer Prev. 2019 28 4 350 354 10.1097/CEJ.0000000000000484 30376467
    [Google Scholar]
  9. Pors J. Weiel J.J. Devereaux K.A. Folkins A.K. Longacre T.A. Fumarate hydratase deficiency should be considered in the differential diagnosis of uterine and extrauterine smooth muscle tumors of uncertain malignant potential (STUMP). Int. J. Gynecol. Pathol. 2022 41 3 268 275 10.1097/PGP.0000000000000797 34108400
    [Google Scholar]
  10. Garg K. Rabban J. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening. Genes Chromosomes Cancer 2021 60 3 210 216 10.1002/gcc.22905 33099845
    [Google Scholar]
  11. Kuroda N. Tsutsui M. Iguchi M. Nobuoka E. Uehara T. Sonobe Y. Morinaga Y. Shibuya S. Oda W. Yanai H. Kawada C. Karashima T. Yamasaki I. Inoue K. Nagashima Y. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms. Ann. Diagn. Pathol. 2020 49 151599 10.1016/j.anndiagpath.2020.151599 32977234
    [Google Scholar]
  12. Gleeson J.P. Nikolovski I. Dinatale R. Zucker M. Knezevic A. Patil S. Ged Y. Kotecha R.R. Shapnik N. Murray S. Russo P. Coleman J. Lee C.H. Stadler Z.K. Hakimi A.A. Feldman D.R. Motzer R.J. Reznik E. Voss M.H. Chen Y.B. Carlo M.I. Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma. Clin. Cancer Res. 2021 27 10 2910 2919 10.1158/1078‑0432.CCR‑20‑4367 33658299
    [Google Scholar]
  13. Webb A. Scott-Mackie P. Cunningham D. Norman A. Andreyev J. O’Brien M. Bensted J. The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer. Ann. Oncol. 1995 6 6 581 587 10.1093/oxfordjournals.annonc.a059248 8573538
    [Google Scholar]
  14. Zhang M. Cheng S. Jin Y. Zhao Y. Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim. Biophys. Acta Rev. Cancer 2021 1875 2 188503 10.1016/j.bbcan.2021.188503 33421585
    [Google Scholar]
  15. Webster B.R. Rompre-Brodeur A. Daneshvar M. Pahwa R. Srinivasan R. Kidney cancer: from genes to therapy. Curr. Probl. Cancer 2021 45 4 100773 10.1016/j.currproblcancer.2021.100773 34261604
    [Google Scholar]
  16. Ganjoo K.N. Uterine sarcomas. Curr. Probl. Cancer 2019 43 4 283 288 10.1016/j.currproblcancer.2019.06.001 31235185
    [Google Scholar]
  17. Gunnala V. Pereira N. Irani M. Lilienthal D. Pirog E.C. Soslow R. Caputo T.A. Elias R. Kligman I. Rosenwaks Z. Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Int. J. Gynecol. Pathol. 2018 37 3 256 261 10.1097/PGP.0000000000000423 28700432
    [Google Scholar]
  18. Pollard P.J. Brière J.J. Alam N.A. Barwell J. Barclay E. Wortham N.C. Hunt T. Mitchell M. Olpin S. Moat S.J. Hargreaves I.P. Heales S.J. Chung Y.L. Griffiths J.R. Dalgleish A. McGrath J.A. Gleeson M.J. Hodgson S.V. Poulsom R. Rustin P. Tomlinson I.P.M. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 2005 14 15 2231 2239 10.1093/hmg/ddi227 15987702
    [Google Scholar]
  19. Lehtonen H.J. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam. Cancer 2011 10 2 397 411 10.1007/s10689‑011‑9428‑z 21404119
    [Google Scholar]
  20. Fu X. Ma W. Zuo Q. Qi Y. Zhang S. Zhao Y. Application of machine learning for high-throughput tumor marker screening. Life Sci. 2024 348 122634 10.1016/j.lfs.2024.122634 38685558
    [Google Scholar]
  21. Gupta S. Swanson A.A. Chen Y.B. Lopez T. Milosevic D. Kipp B.R. Leibovich B.C. Thompson R.H. Herrera-Hernandez L. Cheville J.C. Jimenez R.E. Incidence of succinate dehydrogenase and fumarate hydratase–deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum. Pathol. 2019 91 114 122 10.1016/j.humpath.2019.07.004 31299266
    [Google Scholar]
  22. Ohe C. Smith S.C. Sirohi D. Divatia M. de Peralta-Venturina M. Paner G.P. Agaimy A. Amin M.B. Argani P. Chen Y.B. Cheng L. Colecchia M. Compérat E. Werneck da Cunha I. Epstein J.I. Gill A.J. Hes O. Hirsch M.S. Jochum W. Kunju L.P. Maclean F. Magi-Galluzzi C. McKenney J.K. Mehra R. Nesi G. Osunkoya A.O. Picken M.M. Rao P. Reuter V.E. de Oliveira Salles P.G. Schultz L. Tickoo S.K. Tomlins S.A. Trpkov K. Amin M.B. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase–deficient renal cell carcinoma. Am. J. Surg. Pathol. 2018 42 3 279 292 10.1097/PAS.0000000000001000 29309300
    [Google Scholar]
  23. Baniak N. Tsai H. Hirsch M.S. The differential diagnosis of medullary-based renal masses. Arch. Pathol. Lab. Med. 2021 145 9 1148 1170 10.5858/arpa.2020‑0464‑RA 33406251
    [Google Scholar]
  24. Animesh S. Singh Y.D. A comprehensive study on aptasensors for cancer diagnosis. Curr. Pharm. Biotechnol. 2021 22 8 1069 1084 10.2174/1389201021999200918152721 32957883
    [Google Scholar]
  25. Siafaka P. Çağlar E.Ş. Gündoğdu E.A. Okur N.Ü. New era on combining both imaging and drug delivery to treat cancer. Curr. Pharm. Biotechnol. 2023 24 7 832 855 10.2174/1389201023666220617152334 35718984
    [Google Scholar]
/content/journals/cpb/10.2174/0113892010400394250901101048
Loading
Clinicopathological and Molecular Comparative Analysis of Hereditary vs. Sporadic Fumarate Hydratase-deficient Leiomyomatosis and Renal Carcinoma
Bentham Science Publishers ; https://doi.org/10.2174/0113892010400394250901101048
/content/journals/cpb/10.2174/0113892010400394250901101048
/content/journals/cpb/10.2174/0113892010400394250901101048
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Leiomyomatosis ; FH ; renal carcinoma ; FLRCC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test